Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
4 hedge funds and large institutions have $310K invested in Oasmia Pharmaceutical AB in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
30% less capital invested
Capital invested by funds: $443K → $310K (-$133K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$114K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.7K |
| 3 |
SCM
Sio Capital Management
New York
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$28.3K |
OASM Hedge Fund Activity: Q2 2017 in Review
4 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q2 2017, worth a combined $310K — down 30% from $443K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new OASM positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $114K. The largest seller was Sabby Management, cutting an estimated $28.3K.
- 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q2 2017, up from 3 in Q1 2017.
- Funds reported $310K of Oasmia Pharmaceutical AB stock for Q2 2017, down 30% quarter-over-quarter.
- 1 fund opened new Oasmia Pharmaceutical AB positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Oasmia Pharmaceutical AB buyer in Q2 2017 was Jane Street, an estimated $114K added.
- The largest Oasmia Pharmaceutical AB seller in Q2 2017 was Sabby Management, an estimated $28.3K sold.
Based on aggregated 13F filings for Q2 2017.